# Alnylam Pharmaceuticals, Inc.: financial statements, quarterly

ALNY · Nasdaq · CIK 1178670 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alny.md) · [Financials](/companies/alny/financials.md) · [Filings](/companies/alny/filings.md) · [Insiders](/companies/alny/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alny/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [440 d](/filings/0001628280-26-007497.md) | [494](/filings/0001178670-25-000052.md) | [660](/filings/0001178670-25-000090.md) | [501](/filings/0001628280-25-047345.md) | [593 d](/filings/0001628280-26-007497.md) | [594](/filings/0001178670-25-000052.md) | [774](/filings/0001178670-26-000062.md) | [1,249](/filings/0001178670-26-000076.md) | [1,097 d](/filings/0001628280-26-007497.md) | not reported | [1,291](/filings/0001178670-26-000062.md) | [1,458](/filings/0001178670-26-000076.md) |
| Cost of revenue | $m | [72.0 d](/filings/0001628280-26-007497.md) | [54.6](/filings/0001178670-25-000052.md) | [67.3](/filings/0001178670-25-000090.md) | [82.0](/filings/0001628280-25-047345.md) | [103 d](/filings/0001628280-26-007497.md) | [70.2](/filings/0001178670-25-000052.md) | [142](/filings/0001178670-26-000062.md) | [197](/filings/0001178670-26-000076.md) | [268 d](/filings/0001628280-26-007497.md) | not reported | [298](/filings/0001178670-26-000062.md) | [362](/filings/0001178670-26-000076.md) |
| Research and development | $m | [272 d](/filings/0001628280-26-007497.md) | [261](/filings/0001178670-25-000052.md) | [294](/filings/0001178670-25-000090.md) | [271](/filings/0001628280-25-047345.md) | [300 d](/filings/0001628280-26-007497.md) | [265](/filings/0001178670-25-000052.md) | [324](/filings/0001178670-26-000062.md) | [359](/filings/0001178670-26-000076.md) | [372 d](/filings/0001628280-26-007497.md) | not reported | [413](/filings/0001178670-26-000062.md) | [409](/filings/0001178670-26-000076.md) |
| Selling, general and administrative | $m | [198 d](/filings/0001628280-26-007497.md) | [211](/filings/0001178670-25-000052.md) | [248](/filings/0001178670-25-000090.md) | [221](/filings/0001628280-25-047345.md) | [295 d](/filings/0001628280-26-007497.md) | [240](/filings/0001178670-25-000052.md) | [323](/filings/0001178670-26-000062.md) | [322](/filings/0001178670-26-000076.md) | [325 d](/filings/0001628280-26-007497.md) | not reported | [348](/filings/0001178670-26-000062.md) | [342](/filings/0001178670-26-000076.md) |
| Operating income | $m | [(116) d](/filings/0001628280-26-007497.md) | [(43.4)](/filings/0001178670-25-000052.md) | [48.6](/filings/0001178670-25-000090.md) | [(76.9)](/filings/0001628280-25-047345.md) | [(105) d](/filings/0001628280-26-007497.md) | [18.1](/filings/0001178670-25-000052.md) | [(16.2)](/filings/0001178670-26-000062.md) | [368](/filings/0001178670-26-000076.md) | [132 d](/filings/0001628280-26-007497.md) | not reported | [231](/filings/0001178670-26-000062.md) | [346](/filings/0001178670-26-000076.md) |
| Interest expense | $m | [31.3 d](/filings/0001178670-24-000008.md) | [35.3](/filings/0001178670-24-000023.md) | [33.3](/filings/0001178670-25-000090.md) | [34.4](/filings/0001628280-25-047345.md) | [39.0 d](/filings/0001628280-26-007497.md) | [58.3](/filings/0001628280-26-007497.md) | [61.5](/filings/0001178670-26-000062.md) | [67.5](/filings/0001178670-26-000076.md) | [65.4 d](/filings/0001628280-26-007497.md) | not reported | [82.1](/filings/0001178670-26-000062.md) | [84.4](/filings/0001178670-26-000076.md) |
| Income tax | $m | [0.2 d](/filings/0001628280-26-007497.md) | [2.3](/filings/0001178670-25-000052.md) | [5.7](/filings/0001178670-25-000090.md) | [2.9](/filings/0001628280-25-047345.md) | [(110) d](/filings/0001628280-26-007497.md) | [15.9](/filings/0001178670-25-000052.md) | [30.9](/filings/0001178670-26-000062.md) | [(12.1)](/filings/0001178670-26-000076.md) | [(25.3) d](/filings/0001628280-26-007497.md) | not reported | [13.3](/filings/0001178670-26-000062.md) | [(1,872)](/filings/0001178670-26-000076.md) |
| Net income | $m | [(138) d](/filings/0001628280-26-007497.md) | [(65.9)](/filings/0001628280-25-047345.md) | [(16.9)](/filings/0001628280-25-047345.md) | [(112)](/filings/0001628280-25-047345.md) | [(83.8) d](/filings/0001628280-26-007497.md) | [(18.3)](/filings/0001178670-26-000076.md) | [(72.2)](/filings/0001178670-26-000076.md) | [293](/filings/0001178670-26-000076.md) | [112 d](/filings/0001628280-26-007497.md) | [206](/filings/0001178670-26-000076.md) | [164](/filings/0001178670-26-000076.md) | [2,167](/filings/0001178670-26-000076.md) |
| Diluted EPS | $ per share | not reported | [(0.52)](/filings/0001178670-25-000052.md) | [(0.13)](/filings/0001178670-25-000090.md) | [(0.87)](/filings/0001628280-25-047345.md) | not reported | [(0.14)](/filings/0001628280-26-007497.md) | [(0.55)](/filings/0001178670-26-000062.md) | [2.14](/filings/0001178670-26-000076.md) | not reported | not reported | [1.21](/filings/0001178670-26-000062.md) | [15.72](/filings/0001178670-26-000076.md) |
| Basic EPS | $ per share | not reported | [(0.52)](/filings/0001178670-25-000052.md) | [(0.13)](/filings/0001178670-25-000090.md) | [(0.87)](/filings/0001628280-25-047345.md) | not reported | [(0.14)](/filings/0001628280-26-007497.md) | [(0.55)](/filings/0001178670-26-000062.md) | [2.23](/filings/0001178670-26-000076.md) | not reported | not reported | [1.23](/filings/0001178670-26-000062.md) | [16.19](/filings/0001178670-26-000076.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [813](/filings/0001628280-26-007497.md) | [682](/filings/0001178670-25-000052.md) | [968](/filings/0001178670-25-000090.md) | [1,100](/filings/0001628280-25-047345.md) | [966](/filings/0001628280-26-007497.md) | [1,020](/filings/0001178670-25-000052.md) | [1,114](/filings/0001178670-26-000062.md) | [1,490](/filings/0001178670-26-000076.md) | [1,657](/filings/0001178670-26-000076.md) | not reported | [1,708](/filings/0001178670-26-000062.md) | [1,754](/filings/0001178670-26-000076.md) |
| Current assets | $m | [2,983](/filings/0001178670-25-000026.md) | [2,989](/filings/0001178670-24-000023.md) | [3,173](/filings/0001178670-24-000041.md) | [3,355](/filings/0001178670-24-000053.md) | [3,295](/filings/0001628280-26-007497.md) | [3,268](/filings/0001178670-25-000052.md) | [3,644](/filings/0001178670-25-000090.md) | [3,953](/filings/0001628280-25-047345.md) | [4,051](/filings/0001178670-26-000076.md) | not reported | [4,620](/filings/0001178670-26-000062.md) | [5,113](/filings/0001178670-26-000076.md) |
| Total assets | $m | [3,830](/filings/0001178670-25-000026.md) | [3,824](/filings/0001178670-24-000023.md) | [4,010](/filings/0001178670-24-000041.md) | [4,205](/filings/0001178670-24-000053.md) | [4,240](/filings/0001628280-26-007497.md) | [4,214](/filings/0001178670-25-000052.md) | [4,566](/filings/0001178670-25-000090.md) | [4,852](/filings/0001628280-25-047345.md) | [4,966](/filings/0001178670-26-000076.md) | not reported | [5,559](/filings/0001178670-26-000062.md) | [7,995](/filings/0001178670-26-000076.md) |
| Current liabilities | $m | [968](/filings/0001178670-25-000026.md) | [942](/filings/0001178670-24-000023.md) | [1,055](/filings/0001178670-24-000041.md) | [1,221](/filings/0001178670-24-000053.md) | [1,186](/filings/0001628280-26-007497.md) | [1,076](/filings/0001178670-25-000052.md) | [1,301](/filings/0001178670-25-000090.md) | [1,555](/filings/0001628280-25-047345.md) | [1,466](/filings/0001178670-26-000076.md) | not reported | [1,513](/filings/0001178670-26-000062.md) | [2,063](/filings/0001178670-26-000076.md) |
| Total liabilities | $m | [4,051](/filings/0001178670-25-000026.md) | [4,044](/filings/0001178670-24-000023.md) | [4,013](/filings/0001178670-24-000041.md) | [4,173](/filings/0001178670-24-000053.md) | [4,173](/filings/0001628280-26-007497.md) | [4,098](/filings/0001178670-25-000052.md) | [4,315](/filings/0001178670-25-000090.md) | [4,618](/filings/0001628280-25-047345.md) | [4,177](/filings/0001178670-26-000076.md) | not reported | [4,205](/filings/0001178670-26-000062.md) | [4,391](/filings/0001178670-26-000076.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(221)](/filings/0001628280-26-007497.md) | [(219)](/filings/0001628280-25-047345.md) | [(3.1)](/filings/0001628280-25-047345.md) | [32.4](/filings/0001628280-25-047345.md) | [67.1](/filings/0001178670-26-000076.md) | [426](/filings/0001178670-26-000076.md) | [555](/filings/0001178670-26-000076.md) | [580](/filings/0001178670-26-000076.md) | [789](/filings/0001178670-26-000076.md) | [1,075](/filings/0001178670-26-000076.md) | [1,354](/filings/0001178670-26-000076.md) | [3,604](/filings/0001178670-26-000076.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(59.0) d](/filings/0001178670-24-000041.md) | [359 d](/filings/0001178670-24-000053.md) | [(29.8) d](/filings/0001628280-26-007497.md) | [(81.5)](/filings/0001178670-25-000052.md) | [124 d](/filings/0001178670-25-000090.md) | [43.7 d](/filings/0001628280-25-047345.md) | [(94.7) d](/filings/0001628280-26-007497.md) | [(118)](/filings/0001178670-25-000052.md) | [128 d](/filings/0001178670-26-000062.md) | [297 d](/filings/0001178670-26-000076.md) | [218 d](/filings/0001628280-26-007497.md) | [341 d](/filings/0001178670-26-000076.md) |
| Capital expenditure | $m | [15.9 d](/filings/0001178670-24-000041.md) | [17.1 d](/filings/0001178670-24-000053.md) | [15.3 d](/filings/0001628280-26-007497.md) | [13.0](/filings/0001178670-25-000052.md) | [8.0 d](/filings/0001178670-25-000090.md) | [4.2 d](/filings/0001628280-25-047345.md) | [9.1 d](/filings/0001628280-26-007497.md) | [9.0](/filings/0001178670-25-000052.md) | [14.3 d](/filings/0001178670-26-000062.md) | [12.1 d](/filings/0001178670-26-000076.md) | [23.3 d](/filings/0001628280-26-007497.md) | [69.8 d](/filings/0001178670-26-000076.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [122](/filings/0001178670-23-000023.md) | [124](/filings/0001178670-24-000023.md) | [125](/filings/0001178670-24-000041.md) | [131](/filings/0001178670-24-000053.md) | [126](/filings/0001178670-25-000052.md) | [127](/filings/0001178670-25-000090.md) | [129](/filings/0001628280-25-047345.md) | [130](/filings/0001178670-25-000052.md) | [131](/filings/0001178670-26-000062.md) | [137](/filings/0001178670-26-000076.md) | [138](/filings/0001178670-26-000062.md) | [138](/filings/0001178670-26-000076.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 133,937,576 at 2026-10-23, from the cover of the [10-Q filed 2026-10-29](/filings/0001178670-26-000076.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 15:25 ET. No prices; not investment advice.